Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells 1,862 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Nicole Sweeny sold 1,862 shares of the business’s stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $20.22, for a total transaction of $37,649.64. Following the sale, the insider owned 51,391 shares of the company’s stock, valued at approximately $1,039,126.02. This represents a 3.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Nicole Sweeny also recently made the following trade(s):

• On Monday, February 23rd, Nicole Sweeny sold 3,975 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $15.57, for a total transaction of $61,890.75.

KalVista Pharmaceuticals Stock Up 1.9%

Shares of KALV stock traded up $0.39 on Monday, hitting $20.87. The stock had a trading volume of 703,055 shares, compared to its average volume of 1,194,639. The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of -5.28 and a beta of -0.40. The stock’s 50 day moving average is $17.50 and its 200-day moving average is $15.23. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. KalVista Pharmaceuticals, Inc. has a 52-week low of $9.83 and a 52-week high of $21.31.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in KALV. Tudor Investment Corp ET AL bought a new position in KalVista Pharmaceuticals during the 3rd quarter valued at $24,360,000. Vestal Point Capital LP boosted its stake in KalVista Pharmaceuticals by 152.0% during the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after acquiring an additional 1,140,000 shares during the last quarter. Parkman Healthcare Partners LLC boosted its stake in KalVista Pharmaceuticals by 155.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after acquiring an additional 1,055,940 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in KalVista Pharmaceuticals by 2,258.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock valued at $10,685,000 after acquiring an additional 905,053 shares during the last quarter. Finally, Elmind Capital LP bought a new position in KalVista Pharmaceuticals during the 4th quarter valued at $12,941,000.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. HC Wainwright upped their target price on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, April 13th. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. Citizens Jmp decreased their target price on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research note on Thursday, March 26th. Finally, Stifel Nicolaus upped their target price on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $32.60.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.